Pfizer Sued Due to Worry Lipitor Could Cause Diabetes

Lipitor is the world’s best selling drug available by prescription. Since 1996, when the drug first reached the market, it has produced more than $130 billion in worldwide sales.

In the United States, over 29 million people used Lipitor. The drug is used to lower the levels of cholesterol, but has its side effects.

Now Pfizer, the pharmaceutical giant that produces Lipitor is facing a huge onslaught of lawsuits because of one side effect in particular.

The U.S. Food and Drug Administration analyzed and then allowed the medication to be sold in the market, even though it recognized the existence of a side effect that was dangerous.

Lipitor, the anti-cholesterol pill might cause diabetes. Apparently, females are more apt to develop the sickness after using Lipitor.

The U.S. FDA in 2012 released a warning that drugs from the statins family, as Lipitor can cause a small risk of diabetes.

Because of that, many filed their own lawsuits against Pfizer.

Because the claims increased of late, a federal panel has decided to consolidate them from across the country in a court in Charleston, South Carolina.

Pfizer said it denied all liability and would fight the case in court.

People suffering from diabetes however have had some good news. The new drug Zultophy was just approved by Europe’s European Medicines Agency and likely will arrive in the U.S. sometime over the next couple of years.

The FDA believes in the power of the drug to increase the health condition, as it stated in 2013. The benefits one gains from having lower cholesterol levels are much heavier than the small risks contracting diabetes, the FDA warned.

However, several factors have set the cases for Lipitor diabetes apart from those against other companies.

For one, Lipitor is the best all time selling prescription drug.

When the change in labeling was released back in 2013, a top official in the FDA underscored that the FDA still was behind the medication.

Statins are one class of drugs that block the production in liver of cholesterol to lower heart disease risk.

 

Latest News

Oracle Buying Textura at a Price of $663 Million
Oracle Buying Textura at a Price of $663 Million
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
Verizon Working With Authorities On Sabotage Incidents
Verizon Working With Authorities On Sabotage Incidents
UPS Profit Increases During First Quarter by 10%
UPS Profit Increases During First Quarter by 10%
FY2016 EPS Estimates for Bank of Marin Bancorp  Lifted by Analyst
FY2016 EPS Estimates for Bank of Marin Bancorp Lifted by Analyst
KeyBanc Equities Analysts Lift Earnings Estimates for Brandywine Realty Trust
KeyBanc Equities Analysts Lift Earnings Estimates for Brandywine Realty Trust


Leave a Reply

 
 
© 2006-2016 The Vista Voice. Subscribe